10-Q: Seer Reports Strong Revenue Growth, Reduced Losses

Seer, Inc. announced a significant increase in revenue and a reduction in net losses for the second quarter and first half of 2025, driven by product and service sales, while continuing to manage operating expenses.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 32% to $4.051 million, up from $3.072 million in the same period last year.
• Product revenue grew by 55% to $2.726 million, and service revenue increased by 17% to $0.797 million for the three months ended June 30, 2025.
• Total revenue for the six months ended June 30, 2025, rose by 35% to $8.256 million, compared to $6.138 million in the prior year period.
• Net loss for the three months ended June 30, 2025, decreased by 15% to $(19.424) million, down from $(22.850) million in the prior year.
• Net loss for the six months ended June 30, 2025, decreased by 10% to $(39.372) million, compared to $(43.529) million in the prior year period.
• Operating expenses decreased by 21% for the three-month period and 18% for the six-month period, primarily due to reductions in stock-based compensation and professional services.
• Cash and cash equivalents, along with investments, totaled $263.3 million as of June 30, 2025.
• The company launched the new Proteograph Product Suite, featuring Proteograph ONE Assay and SP200 Automation Instrument in May 2025.
• Net cash used in operating activities increased to $(26.075) million for the six months ended June 30, 2025, from $(20.525) million in the prior year period.
• The company repurchased 3,874,486 shares of Class A common stock for $7.453 million during the three months ended June 30, 2025, under its $25.0 million share repurchase program, with $5.1 million remaining available.

Sentiment

Score: 6

Explanation: The company shows strong revenue growth and effective cost control, leading to reduced net losses. The launch of new products indicates continued innovation. However, it remains unprofitable with negative operating cash flow and faces significant risks from competition, supply chain reliance, and ongoing intellectual property challenges, warranting a cautious but improving outlook.

Positives

• Strong revenue growth of 32% for the quarter and 35% for the six-month period, indicating increasing market adoption of products and services.
• Significant reduction in net loss by 15% for the quarter and 10% for the six-month period, demonstrating improved financial efficiency.
• Operating expenses decreased substantially, with Research and Development down 6% and Selling, General and Administrative down 34% for the quarter, reflecting effective cost management.
• Successful launch of the new Proteograph Product Suite, including the Proteograph ONE Assay and SP200 Automation Instrument, which is expected to enhance scalability, reproducibility, and affordability of proteomic analysis.
• The company maintains a healthy cash and investments balance of $263.3 million, providing liquidity for at least the next twelve months.
• Continued share repurchase activity signals confidence in the company's valuation and commitment to returning value to shareholders.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $431.7 million as of June 30, 2025.
• Cash used in operating activities increased to $(26.075) million for the six months ended June 30, 2025, indicating a higher cash burn rate.
• Interest income decreased by 33% for the quarter and 31% for the six-month period, impacting overall other income.
• A loss of $1.841 million for the quarter and $3.416 million for the six-month period was recognized on the equity method investment in PrognomiQ, Inc.
• Related party revenue experienced a significant decline of 30% for the quarter and 70% for the six-month period.
• Total current assets and total assets decreased from December 31, 2024, to June 30, 2025, reflecting a reduction in overall asset base.

Risks

• The company is an early-stage life sciences technology company with a history of net losses and expects to continue incurring losses, with no assurance of future profitability.
• Operating results may fluctuate significantly due to factors like commercialization success, demand for products, sales cycle length, and macroeconomic conditions.
• The estimated size of the addressable market for the Proteograph Product Suite may be smaller than anticipated, limiting sales potential.
• Commercialization success depends on broad scientific and market acceptance of the Proteograph, which may not be achieved.
• Failure to continuously improve the Proteograph Product Suite or introduce compelling new products and services could harm revenues.
• Health epidemics could adversely impact business operations, customer access to laboratories, and government funding for research.
• Unfavorable U.S. or global economic conditions, including inflation, rising interest rates, or bank failures, could affect capital raising and demand for products.
• Reliance on single suppliers for critical components and instruments (e.g., Hamilton Company) poses supply chain risks.
• Products could have defects or errors, leading to increased costs, damaged reputation, and potential legal claims.
• Compliance with environmental health and safety regulations and handling of hazardous materials could negatively affect operations.
• International business operations expose the company to various regulatory, legal, political, operational, financial, and economic risks.
• The life sciences technology market is highly competitive, with larger, more established companies and internal research efforts posing significant competition.
• The company may need to raise additional capital in the future, which could result in dilution to stockholders or restrictive debt terms.
• Acquisitions or strategic investments, such as in PrognomiQ, could divert management attention, result in dilution, or fail to yield expected benefits.
• The company's ability to use net operating losses (NOLs) to offset future taxable income may be limited by Section 382 of the Internal Revenue Code and state tax laws.
• Ongoing legal proceedings challenging the validity of key patents (e.g., IPR by PreOmics GmbH and Biognosys AG, nullity actions in Germany) could result in loss of patent protection.
• The U.S. law relating to the patentability of certain inventions in the life sciences technology industry is uncertain and rapidly changing, potentially impacting existing or future patents.
• Inability to protect intellectual property rights globally, particularly in countries with less extensive protection, could allow competitors to use similar technologies.
• Reliance on licenses from third parties (e.g., BWH) means loss of these licenses or failure to comply with obligations could severely impact the ability to develop and market products.
• The use of third-party open source software components could require disclosure of proprietary software or lead to compliance issues.
• The multi-class structure of common stock concentrates voting control with certain stockholders, potentially depressing the trading price of Class A common stock.
• Failure to maintain compliance with Nasdaq listing requirements, such as Audit Committee composition, could lead to delisting.
• Significant costs and management resources are required to operate as a public company, including compliance with Sarbanes-Oxley Act.
• Environmental, social, and governance (ESG) matters are subject to evolving expectations, and non-compliance could lead to reputational and cost risks.
• Disruption or unavailability of company facilities or third-party manufacturers' facilities due to natural disasters, public health crises, or other events could interrupt operations.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the near term as it invests in anticipated growth, including broad commercialization of the Proteograph Product Suite, building sales and marketing infrastructure, expanding in-house manufacturing, and ongoing research and development. It believes its current cash and investments are sufficient for at least the next twelve months, but future capital requirements will depend on revenue growth, strategic investments, and operational expansion.

Management Comments

• Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health.
• With the new Proteograph workflow, we believe we have achieved a transformative milestone by significantly improving the scalability, reproducibility, and affordability of deep proteomic analysis.
• These advancements push the boundaries of the original capabilities of the Proteograph Product Suite launched in 2021, addressing historical industry-wide limitations in which deep workflows faced challenges scaling efficiently, manual handling introduced variability, and large-scale studies were hindered by prohibitive costs.
• We expect a highly efficient sales model because our workflow integrates with most existing proteomics laboratories workflows and also complements large-scale genomics research.
• We are focused on removing barriers to access to the Proteograph, including through the Seer Technology Access Center (STAC) service offering.
• We take a long-term view in growing and scaling our business and regularly review opportunities that meet our long-term growth objectives.

Industry Context

The company operates in the evolving life sciences technology market, specifically focusing on proteomics, which is seen as complementary to genomics. It aims to address historical limitations in deep proteomic analysis, such as scalability, reproducibility, and cost, with its new Proteograph Product Suite. The industry faces challenges from established competitors like Agilent Technologies and Thermo Fisher Scientific, as well as emerging proteomic solution providers. The market is also influenced by government funding for research and changing regulatory landscapes for diagnostics and laboratory developed tests (LDTs).

Comparison to Industry Standards

• The filing does not provide specific comparable companies' financial results or project outcomes to benchmark against. It lists competitors such as Agilent Technologies, Bio-Techne, Bruker, Danaher, DiaSorin, Thermo Fisher Scientific, Alamar Biosciences, Nautilus Biotechnology, Quanterix, Quantum-Si, and Standard BioTools, but does not offer a direct performance comparison to these entities.
• The company draws an analogy between the potential impact of its Proteograph Product Suite on the field of proteomics and the impact of Next-Generation Sequencing (NGS) technologies on genomics, suggesting a transformative potential rather than a direct benchmark against current industry standards.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• On October 7, 2024, PreOmics GmbH and Biognosys AG filed a petition for Inter Partes Review before the USPTO (Case No. IPR2024-01473), challenging the validity of select claims of U.S. Patent No. 11,435,360, which is exclusively licensed from The Brigham and Womens Hospital, Inc. (BWH). The Patent Trial and Appeal Board (PTAB) instituted Inter Partes Review of certain claims on April 17, 2025.
• In Germany, an anonymous third party initiated a nullity action against European Patent EP3554681 on November 18, 2024, and a cancellation request against Utility Model Patent No. 202017007363 on January 13, 2025, both exclusively licensed from BWH, alleging lack of novelty and inventive step.
• On May 27, 2025, an anonymous third party filed an Opposition to European Patent 4,056,263, exclusively licensed from BWH, alleging lack of novelty and inventive step.
• A previous lawsuit filed on December 28, 2023, by Giulio Caracciolo and Dipartimento di Medicina Molecolare Sapienza Universita di Roma against the company, BWH, and other inventors, alleging wrongful exclusion as an inventor on certain licensed patents, was dismissed with prejudice on October 25, 2024.

Related Party Transactions

• PrognomiQ, Inc. is a related party.
• Related party receivables amounted to $0.4 million as of June 30, 2025.
• Related party revenue was $0.4 million for the three months ended June 30, 2025, and $0.5 million for the six months ended June 30, 2025.
• The company purchased $10.0 million of PrognomiQ's Series D Preferred Stock on August 12, 2024.
• An additional $1.9 million investment in PrognomiQ's Series D Preferred Stock was made on July 31, 2025.
• The carrying value of the investment in PrognomiQ was $3.9 million as of June 30, 2025.
• A loss of $1.841 million for the three months ended June 30, 2025, and $3.416 million for the six months ended June 30, 2025, was recognized on the equity method investment in PrognomiQ.

Stakeholder Impact

• Shareholders: Benefit from the share repurchase program and potential future value appreciation from commercialization success, but face risks of dilution from future capital raises, stock price volatility, and no expected dividends.
• Employees: Subject to past reductions in force and potential future cost-saving measures, but the company emphasizes attracting and retaining qualified personnel for growth.
• Customers: Expected to benefit from the new Proteograph Product Suite's improved scalability, reproducibility, and affordability, but could be impacted by product defects, supply chain disruptions, or changes in research funding.
• Suppliers: Hamilton Company, as a single contract manufacturer for instruments, and other limited/sole suppliers face increased reliance, with risks if they fail to perform satisfactorily.
• Regulatory Bodies: The company is subject to SEC reporting, Nasdaq listing rules, and evolving FDA regulations, including those for medical devices and LDTs, requiring ongoing compliance efforts.

Next Steps

• Continue broad commercialization of the Proteograph Product Suite.
• Attract, hire, and retain qualified personnel to support growth.
• Continue building sales, marketing, service, support, and distribution infrastructure, including international expansion.
• Build out and expand in-house nanoparticle (NP) manufacturing capabilities.
• Continue research and development of other products and enhancements to the Proteograph Product Suite.
• Implement operational, financial, and management information systems.
• Obtain, maintain, expand, and protect the intellectual property portfolio.
• Build the necessary infrastructure to operate and scale as a public company.
• Evaluate the provisions and impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Evaluate the impact of ASU No. 2023-09 and ASU No. 2024-03 on consolidated financial statements and related disclosures.
• Regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) regarding Audit Committee composition prior to the expiration of the applicable cure period.

Key Dates

Recommendation

The company demonstrates promising revenue growth and improved expense management, leading to a reduced net loss, which are positive indicators for its commercialization efforts. The launch of new products also highlights continued innovation. However, the company remains in an early commercialization stage, incurring significant losses and negative operating cash flow, necessitating future capital raises. Substantial risks persist, including intense competition, reliance on single suppliers, and ongoing legal challenges to key intellectual property, which could significantly impact long-term viability and market position. The share repurchase program is a positive for shareholder value, but the overall financial health and market uncertainties warrant a cautious 'Hold' stance for a seasoned investor, acknowledging both potential and significant hurdles.

Keywords

Proteomics, Life Sciences, Biotechnology, Proteograph, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Operating Expenses, Share Repurchase, Intellectual Property, Commercialization, Research and Development, PrognomiQ, Nasdaq, Corporate Governance